Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SenzaGen ABOSTO:SENZA -0.75%72 Current Ratio is 2.95 as of Mar. 2026, which is 49% below its 10-year median of 5.76. GuruFocus rates OSTO:SENZA with a GF Score™ of 72/100 and a GF Value™ of kr6.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, SenzaGen AB ranks better than 65.26% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. SenzaGen AB's current ratio for the quarter that ended in Mar. 2026 was 2.95.
SenzaGen AB has a current ratio of 2.95. It generally indicates good short-term financial strength.
The historical rank and industry rank for SenzaGen AB's Current Ratio or its related term are showing as below:
OSTO:SENZA'
s Current Ratio Range Over the Past 10 Years
Min: 1.41 Med: 5.76 Max: 30.17
Current: 2.95
During the past 11 years, SenzaGen AB's highest Current Ratio was 30.17. The lowest was 1.41. And the median was 5.76.
OSTO:SENZA's Current Ratio is ranked better than 65.26% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs OSTO:SENZA: 2.95
SenzaGen AB (OSTO:SENZA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
SenzaGen AB Current Ratio Related Terms
SenzaGen AB Current Ratio Historical Data
* Premium members only.
The historical data trend for SenzaGen AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SENZA vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SenzaGen AB (OSTO:SENZA) has a Current Ratio of 2.95 as of Mar. 2026. This is 49% below median its historical median of 5.76. Over the past decade, SenzaGen AB's Current Ratio has ranged from 1.41 to 30.17. According to the industry distribution chart, SenzaGen AB ranks #74 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 34.7%.
Is SenzaGen AB's Current Ratio too high?
SenzaGen AB's current Current Ratio of 2.95 is 49% below median its 10-year median of 5.76. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 30.17. The Medical Diagnostics & Research industry median Current Ratio is 2.10. SenzaGen AB's value of 2.95 is 40.5% above this industry median. Based on the distribution chart, SenzaGen AB ranks #74 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SenzaGen AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #74 out of 213 companies for Current Ratio. This puts SenzaGen AB in the upper half of its industry. The industry median Current Ratio is 2.10. SenzaGen AB's value of 2.95 is 40.5% above this benchmark. Historically, SenzaGen AB's own Current Ratio has ranged from 1.41 to 30.17 over the past decade. While the company's 10-year median is 5.76 vs. the industry median of 2.10, SenzaGen AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SenzaGen AB's current Current Ratio of 2.95 is 40.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SenzaGen AB's current Current Ratio is 2.95, which is 49% below median its own 10-year median of 5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
Based on GuruFocus' analysis, SenzaGen AB (OSTO:SENZA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr6.41, compared to a current price of kr5.30 — trading 17.3% below its estimated fair value. The current Current Ratio is 2.95, which is 49% below median its 10-year median of 5.76 and 40.5% above the Medical Diagnostics & Research industry median of 2.10. SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For SenzaGen AB (OSTO:SENZA), the current Current Ratio is 2.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (OSTO:SENZA) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of kr5.30 is trading 17.3% below its estimated GF Value™ of kr6.41.
GuruFocus considers SenzaGen AB to be Modestly Undervalued.
Key valuation signals for OSTO:SENZA:
Current Ratio: 2.95 (49% below median its 10-year median of 5.76)
GF Value™: kr6.41 vs. price of kr5.30 (17.3% below fair value)
Industry Position: 40.5% above the Medical Diagnostics & Research median (#74 of 213)
No single metric tells the full story. See the OSTO:SENZA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for OSTO:SENZA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SENZA has been successfully added to your 
